A practical reference on fatty acid oxidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-23 and is reviewed periodically as new material appears.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide (Mounjaro and Zepbound) for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea (56% of 2025 revenues); abemaciclib (Verzenio) for the treatment of advanced or metastatic breast cancers (9% of 2025 revenues); dulaglutide (Trulicity) for the treatment of type 2 diabetes (7% of 2025 revenues); ixekizumab (Taltz) for the treatment of autoimmune diseases (6% of 2025 revenues); and empagliflozin (Jardiance) for the treatment of type 2 diabetes (5% of 2025 revenues).
== Instant tea == In 1946, Nestle USA introduced the first instant tea, Nestea. Instant teas are produced from black tea by extracting the liquor from processed portion of tea typically from offgrade black teas; green tea in a smaller proportion has traditionally been used by the instant tea makers as a "clarification agent" - again, in effort to maximize the clarity of color and minimize off-colors created by certain teas that cloud. The extract is concentrated under low pressure, and drying the concentrate to a powder by freeze-drying, spray-drying, or vacuum-drying. Low temperatures tend to be used to minimize loss of flavor. The American market for instant tea powders, which developed quickly following Nestle's introduction, has slackened off considerably over the past quarter century, as Americans have more and more turned to naturally icing their favorite loose teas, as well as preparing iced tea from tea bags, and to ready-to-drink iced teas where the smaller sizes are found in the supermarkets' refrigerated drinks sections and the larger gallon sizes are found in the supermarkets' non-refrigerated drinks sections.
==== United States ==== As of 2018, Zipline was working with the FAA to develop rules for drone operation beyond the line of sight. During the COVID-19 pandemic in 2020, the FAA granted a Part 107 waiver to Novant Health in partnership with Zipline for the delivery of medical supplies and personal protective equipment to facilities in North Carolina. The company plans to offer deliveries to homes. On November 18, 2021, Zipline started a trial service with Walmart for e-commerce shopping deliveries in Pea Ridge, Arkansas. The service, selectable to online shoppers using a special mobile app, could deliver to all residences within 50 miles (80 km) of a particular Walmart store in Pea Ridge during daylight hours. On June 21, 2022, the license "Package Delivery by Drone (Part 135)" was granted. On October 4, 2022, Zipline began commercial delivery services in Salt Lake City, Utah, in partnership with Intermountain Healthcare. On September 18, 2023, the FAA announced it had authorized Zipline to begin making commercial deliveries beyond the line of sight without visual observers. In April 2025, Zipline began making deliveries for Walmart in the Dallas–Fort Worth metroplex using Platform 2 drones.
Former Essendon vice-captain Mark McVeigh was similarly forthright in his praise, claiming Robinson's knowledge of the club's fitness program was "squeaky clean". "I can honestly tell you that everything I took I knew 100 per cent that it was within the WADA and AFL doping regulations," McVeigh continued, affirming his belief that Robinson had done nothing wrong. Following his sacking Robinson began a legal campaign against the club, on the grounds of unfair dismissal. On Thursday 2 October, Essendon reached a $1 million settlement with Robinson to end his unfair dismissal claim. A trial had previously been set for 10 November and several high profile figures, such as Andrew Demetriou and Gillon McLachlan, were expected to testify. In court documents Robinson claimed that an Essendon public relations strategy had been formulated to portray himself and Stephen Dank as "rogue operators" during their tenure.
In the EU member states legislation was introduced in 1998 which had a major effect on UK Pharmacy operations. It effectively prohibited the use of tablet counters for counting and dispensing bulk packaged tablets. Both usage and sales of the machines in the UK declined rapidly as a result of the introduction of blister packaging for medicines.
Sources: en.wikipedia.org
=== Aromatic hydrocarbons === Aromatic hydrocarbons show distinct molecular ion peak.benzylic cleavage is pretty common. When alkyl groups are attached to the ring, a favorable mode of cleavage is to lose a H-radical to form the tropylium cation (m/z 91).
Additional inner doors reduce the loss of temperature when opening the main door. Icing within the ULT freezer should be reduced to a minimum. Modern ULT freezers employ variable speed drives for both the compressors and fans. This has reduced energy consumption a further 30% to typically 8.5 kWh/day.
September 11, 2009: Brazil The Brazilian economy technically left the recession when GDP grew 1.9% in the second quarter of 2009 after having fallen in the first quarter of 2009 and last quarter of 2008. Growth surpassed what was expected by analysts, which was 1.6%.
Three years later, the 2013 revision of the "phenotypes for the disease course" were forced to consider CIS as one of the phenotypes of MS, making obsolete some expressions like "conversion from CIS to MS". Other organizations have proposed later new clinical phenotypes, like HAMS (Highly Active MS).
== External links == IFR/JIC TOF MS Tutorial Jordan TOF Products TOF Mass Spectrometer Tutorial University of Bristol TOF-MS Tutorial Kore Technology – Introduction to Time-of-Flight Mass Spectrometry
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.